Lateral Sinus Floor Elevation in Implant Therapy.
Edentulous; Alveolar Process, Atrophy
About this trial
This is an interventional treatment trial for Edentulous; Alveolar Process, Atrophy
Eligibility Criteria
Inclusion Criteria:
- Provision of informed consent
- Need for L and oral implant placement.
- RBH <4mm
- RBH >4mm, but no T possible (due to anatomy)
Exclusion Criteria:
- Unlikely to be able to comply with the study procedures, as judged by the investigator
- Untreated periodontal disease
- Unfavorable plaque control
- Known or suspected current malignancy
- History of chemotherapy within 5y prior to study
- History of radiation on the head and neck region
- History of other metabolic bone diseases
- Need for systemic corticosteroids
- Current or previous use of intravenous/oral bisphosphonates
- Present alcohol and/or drug abuse
- Involvement in the planning and conduct of the study
- Psychiatric disorders which do not allow a normal treatment outcome
Sites / Locations
- UZ Leuven
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
L-PRF block
DBBM
For the test group the sub-sinus cavity will be filled with L-PRF block and the window will be closed with L-PRF membranes. Eight tubes (9 ml) of venous blood will be collected from the patients. For 6 tubes (red cap) a 12 min centrifugation at 2700 rpm/408g RCF will be followed. Two tubes (white cap) will be centrifuged (IntraSpin, Intra-Lock, Florida, USA) for 3 minutes only to form the Liquid Fibrinogen. The L-PRF clots will be removed from the tubes using surgical tweezers. The clots will be thereafter gently compressed into membranes using a sterile metal box (Xpression, Intra-Lock, Florida, USA). To prepare the L-PRF Block, L-PRF membranes will be cut into small pieces and mixed with DBBM (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The Liquid Fibrinogen will be added to the homogeneous mix, and stirred gently for ± 10 seconds while shaping it to the L-PRF block
For the control group the sub-sinus cavity will be filled with deproteinized bovine bone mineral (DBBM). The product used will be a xenograft (Bio-Oss Small particles, Geistlich AG, Wolhusen, Switzerland). The window will be closed with a collagen membrane (Bio-Gide, Geistlich AG, Wolhusen, Switzerland).